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Abstract: Since its discovery, Helicobacter pylori (H. pylori) has attracted attention in the biomedical
world with its numerous pathophysiologic implications, both gastrointestinal and systemic. Beyond its
well-established carcinogenic properties, emerging evidence also supports ”harmful” proinflammatory and
neurodegenerative roles of H. pylori. On the other hand, H. pylori infection has been proposed to be
”protective” against several diseases, such as asthma and gastroesophageal reflux disease. Eosinophilic
esophagitis (EoE) is a relatively new, allergen/immune-mediated disease, which has also been linked to
these considerations. Main arguments are a postulated shift of immune responses by H. pylori from T
helper 2 (TH 2) to TH 1 polarization, as well as a potential decline of the H. pylori burden with the
dramatic parallel rise of Ε฀Ε: a series of observational studies reported an inverse association. In this
review, we counter these arguments by providing further epidemiological data, which point out that
this generalization might be rather incomplete. We also discuss the limitations of the existing studies
evaluating a possible association. Furthermore, we provide current evidence on common pathogenetic
components, which share both entities. In summary, the claim that H. pylori is protective against EoE
is rather incomplete, and further mechanistic studies are necessary to elucidate a possible association.
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Since its discovery, Helicobacter pylori (H. pylori) has found increasing attention in the biomedical world with its
numerous pathophysiologic implications, both gastrointestinal and systemic. Beyond its well-established carcino-
genic properties, emerging evidence also supports “harmful” proinflammatory and neurodegenerative roles of H.
pylori. On the other hand,H. pylori infection has been proposed to be “protective” against several diseases, such as
asthma and gastroesophageal reflux disease. Eosinophilic esophagitis (EoE) is a relatively new, allergen/immune–
mediated disease, which has also been linked to these considerations. Main arguments are a postulated shift of
immune responses by H. pylori from T helper 2 (TH2) to TH1 polarization, as well as a potential decline of the H.
pylori burden with the dramatic parallel rise of ΕοΕ: a series of observational studies reported an inverse associa-
tion. In this review, we counter these arguments by providing further epidemiological data, which point out that
this generalization might be rather incomplete. We also discuss the limitations of the existing studies evaluating
a possible association. Furthermore, we provide current evidence on common pathogenetic components, which
share both entities. In summary, the claim thatH. pylori is protective against EoE is rather incomplete and further
mechanistic studies are necessary to elucidate a possible association.
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Introduction
Over the last decades,Helicobacter pylori (H. pylori)
has attracted scientific interest with its pleiotropic
manifestations; its demonstrated etiologic associa-
tions include chronic gastritis, peptic ulcer, gastric
adenocarcinoma, and mucosa-associated lymphoid
tissue lymphoma.1–4 Beyond the aforementioned
substantiated pathogenicity of H. pylori locally
in the stomach and duodenum, there have been
emerging data supporting an extended impact
on almost the entire gastrointestinal tract (GIT):
growing evidence supports an association of H.
pylori infection with colorectal neoplasms5,6 and
esophageal adenocarcinoma (EAC) in certain
subpopulations.7,8 Of note, H. pylori has been
identified in the esophagus,9–11 oral and nasal
cavities,12–14 and in normal and colorectal tumor
tissues by the means of polymerase chain reac-
tion or histology.5,6,15 Moreover, a plethora of
extragastric manifestations have been attributed
to H. pylori infection. Clearly confirmed such
manifestations include iron deficiency anemia,
idiopathic thrombocytopenic purpura, vitamin
B12 deficiency, and to a lesser extent, dermatolog-
ical manifestations.16 Additionally, such disorders
include metabolic syndrome–related nonalcoholic
fatty liver disease,5,17–22 currently renamed to
MAFLD (metabolic (dysfunction)–associated
fatty liver disease),23 and neurodegenerative
diseases16,24–26; H. pylori infection has been linked
with mild cognitive impairment, Alzheimer’s
disease (AD), multiple sclerosis, and primary
doi: 10.1111/nyas.14449
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open-angle glaucoma (defined as “ocular AD”),
at least in certain ethnic subpopulations..27–30 In
summary, despite some controversy, an emerging
number of publications supports the pleiotropic
and beyond the stomach/GIT pathogenicity of H.
pylori.
Eosinophilic esophagitis (EoE) is a rather new,
moderately well-comprehended disease,31 first
described in 1993 by Attwood et al.32 and in
1994 by Straumann et al.33 It is defined as an
allergen/immune–mediated entity with the symp-
toms of esophageal dysfunction, most commonly
food impaction, and eosinophilic infiltration of
the esophageal mucosa (more than 15 eosinophils
per high-power field) in the absence of secondary
causes of eosinophilia.34 Specifically, EoE, repre-
senting a principal cause of upper gastrointestinal
(UGI) morbidity, is ranking as the second most
common chronic esophageal disease and the lead-
ing etiology of esophageal food impaction and
dysphagia in both children and young adults.34–36
The natural history of EoE suggests an advancement
of the disease over time, where tissue remodeling
takes place, transiting the initially inflammatory
phenotype to a fibrostenotic one.37,38 Since there
are several reports of a rapid increase of EoE
prevalence34,37,39 and its pathogenicity is only
partly unraveled, it is of particular interest to
develop novel therapies and strategies, which might
change this course and provide an early relief in
affected patients. In this regard, emerging evidence
proposed a “protective” effect of H. pylori infection
on EoE or at least a negative association. Likewise,
H. pylori has been linked in the past to a “protective”
effect of other allergic or nonallergic entities.
The aim of our review was to present current evi-
dence regarding the “protective” effect of H. pylori
on EoE and propose another critical point of view
with further evidence, which counters this protec-
tive consideration. Thus, the former conventional
approach may not reflect the whole truth and pos-
sibly represents only one side of the coin. Moreover,
potential common pathogenic components of both
diseases are reviewed, which might trigger future
mechanistic studies that will further elucidate their
possible association.
“Protective” theory
Despite the fact that H. pylori was officially classi-
fied by the World Health Organization as a definite
(or so-called class I) carcinogen40 as early as in 1994,
the statement that was later reconfirmed in 2012,41
an increasing number of studies began to spread
the speculation of H. pylori possessing “protective”
properties in the late 1990s.42–45 Typical diseases
that have been associated with a beneficial, “pro-
tective” role of H. pylori infection include, among
others, inflammatory bowel disease,46 asthma,47,48
and gastroesophageal reflux disease (GERD).49–52
Regarding the disease of interest, EoE, the first study
that described an inverse association dates back to
2003; Cheung et al.53 reported the lower rates of H.
pylori infection in Australian pediatric patients with
esophageal eosinophilia (EoE) compared with the
control group.53 Four years later, Ronkainen et al.54
revealed that Swedish adult EoE patients were also
characterized by less severeH. pylori infection than
their control counterparts, thus giving rise to sug-
gestions of a “protective” effect in the relevant stud-
ies later.55–60
A “protective” effect of H. pylori has been also
attributed to other than EoE allergic diseases, for
instance, for asthma, with the argument that a per-
centage of asthmatic patientsmay be associatedwith
GERD and H. pylori eradication may also dete-
riorate GERD. The potential “protective” role of
H. pylori is consistent with the so-called “hygiene
hypothesis,” that namely, microbial infections dur-
ing early childhood might be preventive or elimi-
nate asthma and other allergic conditions.47
However, conflicting data are also reported.61,62
Malaysian people, for example, who are character-
ized by a low prevalence of H. pylori infection also
exhibit a low incidence of childhood asthma,GERD,
Barrett’s esophagus (BE), and distal esophageal can-
cers, which would indicate that in this population,
H. pylori infection is not needed as a “protective”
factor against the above-mentioned conditions.63
A recent study with an animal model of asthma
showed that the extract of H. pylori improved
parameters of respiratory inflammation and goblet
cell hyperplasia after repeated allergen exposure.64
RegardingGERD, there is accumulating evidence
supporting the sequence GERD–BE–EAC and H.
pylori implication separately in each single step to
EAC, at least in certain populations.65,66 A large-
scale study (20,918 cases)67 reported that the reduc-
tion in H. pylori infection parallels the decline
in peptic ulcer prevalence, and that the rise in
GERD and/or the reappearance of GERD follow-
2 Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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ing H. pylori therapy is rare. Likewise, contrary to
expectations, another large-scale study with 61,548
in-patient cases with duodenal ulcers apparently
attributed toH. pylori infection had a 70% increased
risk of GERD-related EAC complication.68
In addition,H. pylori infection influences the gas-
trointestinal (GI) microbiome composition includ-
ing species of the stomach, such as Campylobacter
spp. H. pylori infection promotes the gastric micro-
biota dysbiosis, which might contribute to EAC as
implied by the high concentrations of Campylobac-
ter species in the BE biofilm and the predominance
of Gram-negative bacteria.7
In summary, these data might indicate the notion
that H. pylori is not protective against any dis-
eases, including GERD, and its related complica-
tions, including BE and EAC.69
Interestingly, atopic pathologies, including
asthma and EoE, consist of frequent comorbidities
in patients with GERD, though in each disorder,
the indication of an etiologic link is uncertain.70 In
the pediatric population, the highest ranking EoE
comorbidities include asthma (13.4%), GI diseases
(7.26%), allergies (7.01%), and GERD (3.69%).71
Moreover, in adult patients with GERD refractory
to treatment, the prevalence of EoE is 9.7%72
H. pylori and EoE: illuminating the gap
The current global prevalence ofH. pylori infection
seems to be higher than that ofΕοΕ. Its prevalence is
about 58% (varying from 39.9% to 91.7%).7,73 Like-
wise, there has been noticed a remarkable increase
in the incidence of EoE in the last two decades, con-
stituting EoE nowadays as a major etiology of UGI
morbidity.35,37 According to the recent data, a global
average EoE incidence is 3.7/100,000 per year, with
variations ranging from 2.1/100,000 per year in
the Netherlands to 12.8/100,000 per year in the
United States (Ohio).37 EoE is also detected in 1–8%
of symptomatic patients undergoing endoscopy,37
whereas, for instance, comparable recent features
of H. pylori infection are higher (41–63.67%).74,75
Moreover, the current prevalence ofH. pylori infec-
tion in Asia is: Central Asia 79.5%, South Asia
28.6–81%, and Western Asia 49.1–77.2%.76 Addi-
tionally, owing to immigration, H. pylori infec-
tion prevalence in Western countries is high. When
compared with the indigenous populations, immi-
grants and refugees living in Western countries fre-
quently exhibit high rates (72–93%) of H. pylori
infection.7,77,78 Furthermore, for example, in Asia, Q2
H. pylori infection prevalence is 44.4–54.0% among
patients with GERD.79 By contrast, for example,
EoE is uncommon in Singapore80; in South Asia,
EoE prevalence is only 3.2% among patients with
symptoms suggestive for GERD81 or it exhibits a
rising trend82; and in East Asia, EoE prevalence is
9.7% among adult patients with GERD refractory
to treatment.72 Moreover, in the United States, the
mentioned EoE pediatric population exhibit GERD
at a rate of 3.69%.71
Therefore, these data indicate that the conven-
tional claim that declining H. pylori prevalence
has led to a rise of allergic and immune-mediated
inflammatory diseases, including EoE, needs to be
better studied.
Although EoE pathophysiology is not fully elu-
cidated yet, it implicates a plethora of contribut-
ing factors, mainly immunogenetic and environ-
mental ones.38,83–85 Among the variety of environ-
mental factors that have been studied for a poten-
tial contribution to EoE, emerging evidence reveals
the role of microbial imbalance, particularly of
intestinal imbalance, in EoE pathogenesis.38 For
instance, cesarean section and antibiotic exposure
of infants predispose them to the onset of EoE.
Moreover, as in the case of the aforementioned
H. pylori infection–induced microbiota dysbiosis
accompanied by the high concentrations of Campy-
lobacter spp. in the BE biofilm,7 the ingestion of
known EoE-triggering foods can lead to an imbal-
ance of the esophageal microbiota, with the emer-
gence of Campylobacter and Granulicatella genera
on mucosal biopsies.38 Specifically, the accumulat-
ing data indicate a role of bacteria in the com-
plex pathophysiology of EoE; the esophageal micro-
biota, a rich environment consisting of varied bac-
terial species, is critically changed by inflammation,
including EoE; and some pathogens have been pro-
posed as risk factors, while others exhibit protective
effects on EoE pathogenesis.86–88
Focusing on the investigation between H. pylori
infection and EoE,53–60,89,90 the majority of clinical
studies reported an inverse association attributing
“protective” properties toH. pylori infection against
EoE, while some recent multicenter research failed
to show such a negative correlation (Table 1).91
Of note, the latter authors previously claimed that
the inverse association between H. pylori and EoE
might only represent an epiphenomenon as part of
3Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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EoE: ≥ 15 Eos/HPF
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Yes Naive/naive 37.4/39.3 0.97
(0.73–
1.30)
Ag, antigen; CG, control group; CI, confidence interval; BE, Barrett esophagus; EE, esophageal eosinophilia; EoE, eosinophilic
esophagitis; Eos, eosinophils; GEJ, gastroesophageal junction; GERD, gastroesophageal reflux disease; H. pylori, Helicobacter pylori;
HPF, high-power field; Ig, immunoglobulin; NA, not available; OR, odds ratio; PMC, prospective multicenter; PPI, proton pump
inhibitor; PSC, prospective single center; RMC, retrospective multicenter; RSC, retrospective single center; RUT, rapid urease test;
SCJ, squamocolumnar junction; UBT, urea breath test; UES, upper esophageal sphincter.
aGastroesophageal reflux esophagitis, Barrett esophagus, eosinophilic gastroenteritis, inflammatory bowel disease, or other etiologies
for eosinophilia, (D), definite, (Po), possible, (P), probable.
a more general change in human microecology.92
Other experts also share the same point of view.93
Moreover, it has been repeatedly investigated,
whether there is an association between H. pylori
infection and EoE37,38,94–96; the majority of clinical
studies53–60 report an inverse association or “neg-
ative correlation.” However, the aforementioned
case–control studies are characterized by multi-
ple methodological limitations (Table 1), which
may confine the interpretability or even dispute
their results.91 For instance, the two largest stud-
ies performed by the same coauthors57,59 were of
retrospective nature. Moreover, the protocol for
obtaining gastric mucosa biopsy specimens was not
provided59 (or mentioned that only 3.9% of biopsy
sets were compliant with the Sydney System57) and
no additional data regarding previous proton pump
inhibitor (PPI) discontinuation before biopsies were
available. These data about PPI withdrawal were not
provided in another study, which also used histol-
ogy as a diagnostic modality.58 Therefore, concerns
have been raised about false-negative H. pylori sta-
tus in these studies. In the first large studies,54,59
EoE cases have been identified by any EoE, with-
out taking into account the histological cutoff of 15
eosinophils per high-power field. Besides, data in
regard to previous eradication regimens54,56–59 or
esophageal symptoms54,56–59 were absent or incom-
plete in some patients. As far as the prospec-
tive study of Ma et al.89 is concerned, the small
sample size, the usage of serology as a diag-
nostic modality for H. pylori infection, and the
lack of esophageal biopsies in the control group
question the reported results. It needs to be
5Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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emphasized that serology (IgG anti-H. pylori anti-
bodies) cannot discriminate between active or pre-
vious H. pylori infection, and this may lead to a
substantial number of false-positive results. Note-
worthy is also the point that the majority of these
studies found a surprisingly extremely low preva-
lence of H. pylori infection53,57–60 in both con-
trol and EoE groups (Table 1). Of note, a recent
comprehensive systemic review and meta-analysis
assessed the global prevalence of H. pylori infec-
tion; The lowest H. pylori prevalence rates were
found in Switzerland (18.9%), Denmark (22.1%),
New Zealand (24.0%), Australia (24.6%), and Swe-
den (26.2%).76 Even these lowest rates are five to
ten times higher than the estimatedH. pylori preva-
lence in the four previous case–control studies.57–60
In the only large prospective (808 individuals) and
multicenter (23 centers) study,91 where these limita-
tions from previous case–control studies were taken
into account, no inverse association was reported
between H. pylori infection and EoE; no significant
difference in the prevalence of H. pylori infection
was recognized between cases and controls in both
children (42% versus 46%) and adults (38% versus
38%). A borderline inverse association could be ver-Q4
ified for allergic rhinitis and atopy, but not for food
allergy or even asthma. These findings questioned
the protective role of H. pylori infection against
allergic pathologies, including EoE. A second ear-
lier study90 with prospective design and H. pylori
diagnosis based on histology failed to show statisti-
cal significance for H. pylori infection between EoE
and control groups (Table 1). Interestingly, similar
further results have been shown by other research
groups, which claimed conflicting inverse or pos-
itive associations depending on either the socioe-
conomic environment or national descent, point-
ing at the existence of potentially not considered
confounders, which might, however, influence this
association.97,98
Two major arguments of the supporters of the
protective H. pylori viewpoint are the follow-
ing: (1) the bacterium shapes a TH1 immune
response, whereas EoE as an allergic reaction
is classically TH2-polarized, and (2) the already
criticized consideration that the increase of EoE
prevalence/incidence is correlated with a currently
undocumented rapid decrease in H. pylori preva-
lence over the past several decades, which matches
the increase in EoE prevalence.37,38,83 These claims
seem to be incomplete and represent only one side
of the coin.
It is recognized that H. pylori infection does not
induce a pure TH1-polarized immune response,
but rather a mixed, TH1/TH17 predominant
response99; it also induces the differentiation of
anti-inflammatory TH2 cells.4,100 Additionally,
EoE patients with the late-onset and more intense
allergic inflammation are characterized by a mixed
TH1 and TH17 cytokine milieu for supporting the
development of TH interleukin (IL)-17 positive
cells.101 In a recent EoE study with pediatric and
adult cases, it was demonstrated that TH17 cells
have a role in EoE pathogenesis.102
Concerning the second epidemiological argu-
mentation of “protective” H. pylori supporters, it
may be only a coincidental event without, an eti-
ologic association. In this respect, for example, it
has to be acknowledged that recent studies also
do exist reporting no statistically significant differ-
ence in incidence rates of EoE by year103; never-
theless, there was a significantly lower incidence
rate in individuals aged less than 16 compared
with those aged 16 or more. Moreover, a Mexican
study that included adult patients with esophageal
food impaction reported low prevalence (11.7%)
of biopsy-proven EoE, whereas peptic stenosis was
identified as the most common etiology.104
These data, despite the several methodological
concerns, which confine interpretability (among
others retrospective design, various bias or inabil-
ity to rule-out GERD), are in contrast to previous
reports of increasing prevalence rates and might
reflect a leveling off of EoE prevalence.
Further evidence has accumulatedwith the elapse
of time for both entities, which propose indepen-
dently, that both EoE and H. pylori infection share
common pathogenetic components (Fig. 1).
Galectins represent one typical paradigm; they
belong to the lectin superfamily, a group of endoge-
nous glycan-binding proteins, which can interact
with glycosylated receptors expressed by a plethora
of immune cells.105 Galectin (Gal)-3 plays a role
in H. pylori colonization of the gastric mucosa,
as well as in the local immune response and
chronic gastric implications.106 Gal-3 might consti-
tute an essential host factor for keeping H. pylori
infection and colonization at subclinical levels.
H. pylori–related Gal-3 also contributes to chronic
cardiovascular, kidney, and brain disorders in
6 Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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Figure 1. Proposed common pathogenetic components betweenHelicobacter pylori infection and eosinophilic esophagitis. EoE,
eosinophilic esophagitis; Ig, immunoglobulin; IL, interleukin, STAT, signal transducer and activator of transcription; TGF, trans-
forming growth factor; TLR, Toll-like receptors; TNF, tumor necrosis factor; Tregs, regulatory T cells, TSLP, thymic stromal lym-
phopoietin.
decompensated cirrhosis.107 In addition, Gal-3
plays a crucial proinflammatory role in allergic
asthma by promoting eosinophil migration and
trafficking108; Gal-3 is upregulated during allergic
inflammatory response in atopic dermatitis.109 In
respect to other than EoE allergic diseases, which
are IgE-dependent, it has also been reported in vitro
Gal-3 to be essential for IgE-dependent activation
of human basophils.110 The last granulocyte pop-
ulation is a recognized immune cell type impli-
cated in both H. pylori infection virulence and EoE
pathogenicity.38,111 Moreover, a proteomic analy-
sis of the esophageal mucosa in patients with EoE
showed a distinct abundance and nitrosylation pro-
file, most remarkably in distal biopsies.112 Gal-3
expression and S-nitrosylation were upregulated,
which might explain a probable role in mucosal
inflammation, and thus further research is needed
to reveal in-depth the possible involvement of H.
pylori–related Gal-3 in EoE pathophysiology.
Another aspect of EoE pathogenesis includes
the mast cell population actively involved in the
development of EoE.113,114 Mast cells may promote
inflammation and fibrosis in EoE, by secreting fac-
tors, such as transforming growth factor (TGF)-β,
a proinflammatory cytokine that induces smooth
muscle contractility contributing to esophageal dys-
function and tryptase, which promotes prolifera-
tion and collagen secretion.84,115 Beyond EoE, TGF-
β seems to be a substantial mediator in H. pylori
infection pathogenesis.116 TGF-β–inducing protein
of H. pylori may mediate the immune response
7Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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and contribute to the pathogenesis of H. pylori
infection.117 Additionally, H. pylori–induced cyto-
toxin VacA exhibits chemotactic activities to the
bone marrow–derived mast cells (BMDMCs) and
induces BMDMCs for the production of proinflam-
matory cytokines, including tumor necrosis factor
(TNF)-α, which has been reported to be overex-
pressed in esophageal epithelial cells of EoE.118,119
Of note, TNF-α is known for its ability to stimulate
mast cells.120,121 Moreover, IL-33 is a proapoptotic
molecule, which is upregulated in active EoE.38,101
IL-33 mRNA from the gastric epithelium and pro-
tein expression was also increased in both mice
and human patients with H. pylori infection, which
was positively associated with the bacterial load
and the degree of gastritis.122 IL-33 production was
promoted via extracellular signal–regulated kinase
signaling pathway activation by gastric epithelial
cells in a cagA-dependent manner during H. pylori
infection, which resulted in increased inflammation
and bacterial burden within the gastric epithelium.
Therefore,H. pylori–related mast cell–related TGF-
β, TNF-α, and/or IL-33 might also contribute to the
pathophysiology of EoE, and thus further research
is needed to elucidate this field.
A further type of granulocyte polymorphonu-
clear cells with a special interest in EoE are
basophils.38 Several studies have emphasized the
crucial role of basophils in allergic diseases includ-
ing EoE; they may play a role in the complex
pathophysiology of EoE.123 In murine models of
EoE, allergic skin sensitization promoted EoE via
the IL-33–basophil axis.124 The gastric mucosa of
H. pylori–infected patients (affected by moderate
and severe gastritis) is also infiltrated by basophils,
and H. pylori–derived peptide (H. pylori (2–20))
appears to be a potent basophil chemoattractant.111
The potential role of H. pylori (2–20) basophil
chemoattractant, however, in the pathogenesis of
EoE remains to be elucidated.
Regulatory T cells (Treg) play a compelling
role in the pathophysiology of EoE. Regard-
ing H. pylori infection, some data indicate that
both TH1 and TH17 cells could be protective or
pathogenic, whereas Treg and TH2 cells achieve anti-
inflammatory impacts duringH. pylori infection.125
In a pediatric study, an increased number of infil-
trating Treg positive for forkhead box P3 (FoxP3)
has been reported in esophageal biopsies of EoE
patients.126 Likewise, an increased number of
FoxP3-positive Treg was reported in H. pylori–
positive gastritis.127 However, the potential role of
H. pylori–related Treg in the pathophysiology of EoE
remains to be defined.
Other molecules of interest are the antimicro-
bial peptides, defensins. Changes in the level of
human β-defensins (hBDs) and other antimicrobial
peptides are connected with various inflamma-
tory and allergic diseases, such as asthma, thereby
leading to novel treatments for many allergic
diseases.128 The diminished esophageal expression
of hBD1 and hBD3 was reported in EoE, deducing
that it might render the esophageal mucosa more
susceptible to the onset or progression of EoE.129
Likewise, H. pylori induces defensin release linked
with chronic inflammatory tissue damage, while H.
pylori can evade the attack by defensins130; human
defensins may also play a role in H. pylori–related
neurodegenerative disorders.130,131 A potential
impact of H. pylori–related inappropriate defensin
expression in EoE pathogenesis remains to be
clarified.
With respect to aforementionedH. pylori–related
neurodegenerative and the rest of the extragas-
tric pathologies, where H. pylori serves as a com-
mon denominator, two observations appear to be
of interest for EoE: (1) although EoE is uncommon
in elderly patients who exhibit dementia indices, it
often leads to clinically overt dysphagia.132 In this
regard, H. pylori–related apolipoprotein E (ApoE)-
4 polymorphism, the most common known genetic
risk factor for AD onset, could be connected with
dysphagic symptoms in such elderly patients; an
association between H. pylori infection and ApoE4
polymorphism contributes to the pathogenesis of
AD and, possibly, of glaucoma.133 (2) MAFLD
(where the evidence of H. pylori infection as the
contributor accumulates5,17–22) and EoE seem to be
the common topic in pediatric gastroenterology.134
Lastly, the genetic factors are linkedwith EoE.38,83
Genes that contribute to EoE progression include
calpain 14 (CAPN14), Toll-like receptors (TLR),
TSLP, EMSY (or GL002, C11orf30), leucine-rich
repeat containing 32 (LRRC32), STAT6, and the
ankyrin repeat domain 27 (ANKRD27).38,135 Some
of the aforementioned genes, such as TLR2, TSLP,
and STAT6, have also been linked with H. pylori
infection.136–140 A possible role of these H. pylori–
related genes in EoE pathogenesis remains to be
clarified.
8 Ann. N.Y. Acad. Sci. xxxx (2020) 1–13 © 2020 New York Academy of Sciences.
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Conclusion
H. pylori displays a wide spectrum of pathogenic-
ity and many intriguing extragastric manifesta-
tions. The claim that H. pylori protects from EoE
seems rather incomplete. Mechanistic studies in
both human patients and animalmodelsmimicking
EoE investigating the aforementioned commonali-
ties between two entities will elucidate pathogenic
pathways and unravel new promising therapies.
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Graphical Abstract & Image
The aim of our review was to present current evidence regarding the “protective” effect of H. pylori on
EoE and propose another critical point of view with further evidence, which counters this protective
consideration. Thus, the former conventional approach may not reflect the whole truth and possibly
represents only one side of the coin. Moreover, potential common pathogenic components of both
diseases are reviewed, which might trigger future mechanistic studies that will further elucidate their
possible association.
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